Setmelanotide
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bardet-Biedl Syndrome
Conditions
Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
Trial Timeline
Mar 8, 2022 → Nov 8, 2024
NCT ID
NCT04966741About Setmelanotide
Setmelanotide is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Bardet-Biedl Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04966741. Target conditions include Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772597 | Phase 2 | Active |
| NCT06596135 | Phase 3 | Recruiting |
| NCT04966741 | Phase 3 | Completed |
| NCT04725240 | Phase 2 | Completed |
| NCT04348175 | Phase 1 | Completed |
| NCT03651765 | Phase 2/3 | Completed |
| NCT03262610 | Phase 2 | Completed |
| NCT03013543 | Phase 2 | Completed |
Competing Products
2 competing products in Bardet-Biedl Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide, administered subcutaneously [SC], once daily. | Rhythm Pharmaceuticals | Pre-clinical | 20 |